Khaled Musallam on Management of Transfusion-Dependent β-Thalassaemia in LMICs
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”On the first day of 2026, I’m delighted to share one of my favourite pieces of work—published today in The Lancet Haematology and featured on the cover.
This Viewpoint introduces a practical decision matrix to help prioritise novel therapies for thalassemia—including disease-modifying and gene therapies—based on need, benefit, and risk, particularly in settings where access remains limited.
It also proposes realistic alternatives when standard options are not available.
The work builds on Thalassaemia International Federation guidelines, the best available trial and real-world evidence, and expert consensus from a truly global group of haematologists, transplant physicians, patient representatives, translational scientists, and trialists—bringing together 200+ years of collective clinical experience across Asia, the Middle East, Europe, and North America.
Grateful to an exceptional group of co-authors and hopeful this framework helps support more equitable, evidence-based care for patients worldwide.”
Read the full article in The Lancet Hematology.
Article: Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
Authors: Khaled Musallam, Sujit Sheth, Maria Domenica Cappellini, Farrukh Shah, Stefano Rivella, Vijay G Sankaran et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis